We are live on
!
Find out more
CS
Candriam SCA Portfolio holdings
AUM
$19.3B
1-Year Est. Return
39.18%
This Fund
S&P 500
This Quarter
Est. Return
+8.76%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$13.8B
AUM Growth
-$581M
(-4%)
Cap. Flow
-$2.79B
Cap. Flow
% of AUM
-20.16%
Top 10 Holdings %
Top 10 Hldgs %
25.18%
Holding
905
New
29
Increased
148
Reduced
448
Closed
194
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$66.4M |
| 2 |
Valero Energy
VLO
|
+$28.9M |
| 3 |
SLB Ltd
SLB
|
+$24.8M |
| 4 |
BNY
Bank of New York Mellon
BNY
|
+$22.6M |
| 5 |
PepsiCo
PEP
|
+$20.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$182M |
| 2 |
Apple
AAPL
|
+$148M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$90.9M |
| 4 |
Amgen
AMGN
|
+$72.1M |
| 5 |
Tesla
TSLA
|
+$66.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 31.26% |
| 2 | Technology | 28.78% |
| 3 | Financials | 8.15% |
| 4 | Consumer Discretionary | 7.54% |
| 5 | Industrials | 7.28% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
226
Ralph Lauren
RL
$22.6B
| $11.6M | 0.08% |
94,203
+4,990
| +6% | +$576K |
|
227
Arvinas
ARVN
$530M
| $11.6M | 0.08% |
467,553
-27,394
| -6% | -$705K |
|
228
Sarepta Therapeutics
SRPT
$1.68B
| $11.5M | 0.08% |
100,000
-22,194
| -18% | -$2.86M |
|
229
Eversource Energy
ES
$28.1B
| $11.4M | 0.08% |
160,626
-20,370
| -11% | -$1.52M |
|
230
Sysco
SYY
$40.2B
| $11.3M | 0.08% |
152,462
+92,381
| +154% | +$6.83M |
|
231
LKQ Corp
LKQ
$6.69B
| $11.3M | 0.08% |
193,211
-14,356
| -7% | -$799K |
|
232
Kymera Therapeutics
KYMR
$9.05B
| $11.2M | 0.08% |
488,306
-23,170
| -5% | -$664K |
|
233
Oracle
ORCL
$345B
| $11.1M | 0.08% |
93,280
-3,373
| -3% | -$349K |
|
234
Bentley Systems
BSY
$10.2B
| $10.9M | 0.08% |
201,060
-14,796
| -7% | -$690K |
|
|
SAGE
235
DELISTED
Sage Therapeutics
SAGE
| $10.7M | 0.08% |
227,000
+137,000
| +152% | +$6.82M |
|
236
Deere & Co
DE
$169B
| $10.7M | 0.08% |
26,322
-1,613
| -6% | -$617K |
|
237
ConocoPhillips
COP
$141B
| $10.6M | 0.08% |
102,726
-17,119
| -14% | -$1.76M |
|
238
Denali Therapeutics
DNLI
$3.74B
| $10.6M | 0.08% |
357,878
| – | – |
|
|
CERE
239
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $10.4M | 0.08% |
327,221
| – | – |
|
240
Macy's
M
$6.57B
| $10.3M | 0.07% |
639,858
-12,756
| -2% | -$204K |
|
241
CBRE Group
CBRE
$42.1B
| $10.2M | 0.07% |
126,371
+69,250
| +121% | +$5.18M |
|
242
Nurix Therapeutics
NRIX
$2.43B
| $10.2M | 0.07% |
1,019,822
+119,734
| +13% | +$1.22M |
|
243
T-Mobile US
TMUS
$190B
| $10.1M | 0.07% |
72,904
-9,991
| -12% | -$1.4M |
|
|
DAY
244
DELISTED
Dayforce
DAY
| $10.1M | 0.07% |
150,163
+12,501
| +9% | +$804K |
|
245
Jabil
JBL
$32.6B
| $9.97M | 0.07% |
+92,369
| New | +$8.13M |
|
246
West Fraser Timber
WFG
$5.18B
| $9.9M | 0.07% |
115,133
-6,731
| -6% | -$508K |
|
247
Host Hotels & Resorts
HST
$17.1B
| $9.78M | 0.07% |
580,922
+495,415
| +579% | +$8.3M |
|
248
Kroger
KR
$35.5B
| $9.75M | 0.07% |
207,489
-357,155
| -63% | -$17M |
|
249
Coupang
CPNG
$28.6B
| $9.64M | 0.07% |
554,000
+112,400
| +25% | +$1.83M |
|
250
IDEAYA Biosciences
IDYA
$3.54B
| $9.64M | 0.07% |
410,020
+129,703
| +46% | +$2.67M |
|
Similar funds
PCM
A
MGP
LF
SOMRS
BPA
MIM
Candriam SCA's Q2 2023 Portfolio in Review
As of Q2 2023, Candriam SCA held 905 positions worth $13.8B, down 4% from $14.4B the previous quarter. Its ten largest holdings account for 25% of the portfolio.
Candriam SCA withdrew a net $2.79B in Q2 2023, closing 194 positions and reducing 448 holdings. Its most notable exit was Thomson Reuters, an estimated $19.8M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 31% of assets, up from 31% a quarter earlier, followed by Technology and Financials.
Against the trend, Candriam SCA opened a new position in Vir Biotechnology worth $8.7M.
- Candriam SCA's largest Q2 2023 buy was Vir Biotechnology: 354,645 shares worth $8.7M.
- Candriam SCA added most to Lam Research in Q2 2023, an estimated $66.4M increase.
- Candriam SCA's biggest Q2 2023 reduction was Microsoft, cutting an estimated $182M.
- Candriam SCA fully exited Thomson Reuters in Q2 2023, selling an estimated $19.8M.
- Candriam SCA's ten largest holdings make up 25% of its $13.8B portfolio in Q2 2023.
- Candriam SCA opened 29 new positions and closed 194 in Q2 2023.
- Candriam SCA's portfolio value fell 4% quarter-over-quarter to $13.8B.
Based on Candriam SCA's 13F filing for Q2 2023, filed 8 Aug 2023.